CA2320302A1 - Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery - Google Patents
Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery Download PDFInfo
- Publication number
- CA2320302A1 CA2320302A1 CA002320302A CA2320302A CA2320302A1 CA 2320302 A1 CA2320302 A1 CA 2320302A1 CA 002320302 A CA002320302 A CA 002320302A CA 2320302 A CA2320302 A CA 2320302A CA 2320302 A1 CA2320302 A1 CA 2320302A1
- Authority
- CA
- Canada
- Prior art keywords
- vector
- histamine
- fgf
- protein
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2177398A | 1998-02-11 | 1998-02-11 | |
| US09/021,773 | 1998-02-11 | ||
| PCT/US1999/002702 WO1999040945A2 (en) | 1998-02-11 | 1999-02-09 | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2320302A1 true CA2320302A1 (en) | 1999-08-19 |
Family
ID=21806073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002320302A Abandoned CA2320302A1 (en) | 1998-02-11 | 1999-02-09 | Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1053025A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002502885A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20010015915A (cg-RX-API-DMAC7.html) |
| CN (2) | CN100350979C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2663799A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2320302A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA019099B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL137765A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ545047A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999040945A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA991102B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| US20020103147A1 (en) | 1997-09-05 | 2002-08-01 | Hammond H. Kirk | Gene therapy for congestive heart failure |
| WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| HK1048593A1 (zh) * | 1999-11-05 | 2003-04-11 | The Regents Of The University Of California | 用於通过体内基因输送治疗心血管疾病的技术和组合物 |
| CA2412847A1 (en) * | 2000-06-30 | 2002-01-10 | Collateral Therapeutics, Inc. | Dual recombinant gene therapy compositions and methods of use |
| JP2005052001A (ja) * | 2001-07-05 | 2005-03-03 | Takara Bio Inc | 遺伝子治療剤 |
| EP2236153A3 (en) | 2005-01-25 | 2012-08-22 | Five Prime Therapeutics, Inc. | Compositons and methods for treating cardiac conditions |
| PL2044199T3 (pl) * | 2006-07-25 | 2013-04-30 | Celladon Corp | Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej |
| JP5290290B2 (ja) | 2007-07-18 | 2013-09-18 | シルク・ロード・メディカル・インコーポレイテッド | 頚動脈血流の逆流を確立する方法およびシステム |
| EP2244740A1 (en) | 2008-02-19 | 2010-11-03 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
| US20130096500A1 (en) * | 2011-07-07 | 2013-04-18 | Gabor Rubanyi | Nucleic acid based cardiovascular therapeutics |
| WO2014160887A2 (en) * | 2013-03-28 | 2014-10-02 | Silk Road Medical, Inc. | Methods and systems for establishing retrograde carotid arterial blood flow |
| WO2019089385A1 (en) | 2017-11-02 | 2019-05-09 | Silk Road Medical, Inc. | Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100242A (en) * | 1995-02-28 | 2000-08-08 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
| US5869230A (en) * | 1995-03-30 | 1999-02-09 | Beth Israel Hospital Association | Gene transfer into the kidney |
| WO1999017807A1 (en) * | 1997-10-08 | 1999-04-15 | Cobra Therapeutics Ltd. | Use of a vasoactive compound in the enhancement of gene delivery |
| WO1999018792A1 (en) * | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
-
1999
- 1999-02-09 EP EP99906814A patent/EP1053025A2/en not_active Withdrawn
- 1999-02-09 JP JP2000531196A patent/JP2002502885A/ja active Pending
- 1999-02-09 AU AU26637/99A patent/AU2663799A/en not_active Abandoned
- 1999-02-09 CA CA002320302A patent/CA2320302A1/en not_active Abandoned
- 1999-02-09 WO PCT/US1999/002702 patent/WO1999040945A2/en not_active Ceased
- 1999-02-09 EP EP05026675A patent/EP1695719A1/en not_active Withdrawn
- 1999-02-09 EA EA200000828A patent/EA019099B1/ru not_active IP Right Cessation
- 1999-02-09 CN CNB998049425A patent/CN100350979C/zh not_active Expired - Fee Related
- 1999-02-09 IL IL13776599A patent/IL137765A0/xx unknown
- 1999-02-09 CN CNA2007101808364A patent/CN101186928A/zh active Pending
- 1999-02-09 KR KR1020007008781A patent/KR20010015915A/ko not_active Ceased
- 1999-02-09 NZ NZ545047A patent/NZ545047A/en not_active IP Right Cessation
- 1999-02-11 ZA ZA9901102A patent/ZA991102B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999040945A2 (en) | 1999-08-19 |
| ZA991102B (en) | 2000-03-31 |
| IL137765A0 (en) | 2001-10-31 |
| WO1999040945A3 (en) | 1999-09-30 |
| EP1695719A1 (en) | 2006-08-30 |
| CN101186928A (zh) | 2008-05-28 |
| CN1301181A (zh) | 2001-06-27 |
| CN100350979C (zh) | 2007-11-28 |
| JP2002502885A (ja) | 2002-01-29 |
| EA200000828A1 (ru) | 2001-02-26 |
| AU2663799A (en) | 1999-08-30 |
| EA019099B1 (ru) | 2014-01-30 |
| KR20010015915A (ko) | 2001-02-26 |
| EP1053025A2 (en) | 2000-11-22 |
| NZ545047A (en) | 2009-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5792453A (en) | Gene transfer-mediated angiogenesis therapy | |
| US6174871B1 (en) | Gene therapies for enhancing cardiac function | |
| AU767662B2 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF | |
| US20090082293A1 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| AU784392B2 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| EP1695719A1 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| CA2289600C (en) | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes | |
| AU2006200170B2 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU706050C (en) | Gene transfer-mediated angiogenesis therapy | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU4754199A (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2004200697A1 (en) | Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20160623 |